| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $16,639,005 | 33 | 100 |
| Patel Kavita | director | 0 | $0 | 9 | $884,542 | $-884,542 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER | 0 | $0 | 8 | $4.02M | $-4.02M |
| Heery Christopher | CHIEF MEDICAL OFFICER | 0 | $0 | 11 | $4.73M | $-4.73M |
| Elghandour Rami | SEE REMARKS | 0 | $0 | 5 | $7.01M | $-7.01M |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $16.64M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $182.5M and sold $70.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
| 2025-11-17 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 340 0.0006% | $90.00 | $30,600 | -18.64% | |
| 2025-10-15 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 5,364 0.0095% | $91.04 | $488,315 | -6.21% | |
| 2025-10-06 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 1,064 0.002% | $86.22 | $91,733 | +2.79% | |
| 2025-10-03 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 4,882 0.0092% | $86.00 | $419,870 | +1.92% | |
| 2025-09-30 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 21,034 0.0376% | $81.28 | $1.71M | +5.51% | |
| 2025-09-29 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 73 0.0001% | $80.16 | $5,852 | +9.49% | |
| 2025-09-26 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 12,396 0.0225% | $80.12 | $993,155 | +8.37% | |
| 2025-09-19 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 300 0.0006% | $80.00 | $24,000 | +10.36% | |
| 2025-09-18 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 3,343 0.006% | $80.01 | $267,468 | +7.24% | |
| 2025-06-10 | Sale | Patel Kavita | director | 1,500 0.0028% | $67.36 | $101,040 | +8.24% | |
| 2025-05-27 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 12,235 0.023% | $64.14 | $784,777 | +16.00% | |
| 2025-05-20 | Sale | Patel Kavita | director | 1,500 0.0026% | $58.43 | $87,645 | +18.55% | |
| 2025-04-29 | Sale | Patel Kavita | director | 1,500 0.0027% | $64.20 | $96,300 | +10.01% | |
| 2025-04-08 | Sale | Patel Kavita | director | 1,500 0.0028% | $57.50 | $86,250 | +31.77% | |
| 2025-03-18 | Sale | Patel Kavita | director | 1,500 0.0028% | $71.64 | $107,460 | +0.54% | |
| 2025-02-26 | Sale | Elghandour Rami | SEE REMARKS | 38,300 0.0727% | $62.02 | $2.38M | +16.35% | |
| 2025-02-25 | Sale | Patel Kavita | director | 1,500 0.0027% | $63.16 | $94,740 | +11.81% | |
| 2025-02-24 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 10,155 0.0188% | $63.79 | $647,773 | +11.08% | |
| 2025-02-04 | Sale | Patel Kavita | director | 1,500 0.0028% | $64.57 | $96,855 | +2.74% | |
| 2025-01-14 | Sale | Patel Kavita | director | 1,500 0.0028% | $65.87 | $98,801 | +6.62% |
| Elghandour Rami | SEE REMARKS | 149186 0.2693% | $10.21M | 0 | 12 | |
| Gilson Michelle | CHIEF FINANCIAL OFFICER | 8466 0.0153% | $579,497.70 | 0 | 17 | |
| Heery Christopher | CHIEF MEDICAL OFFICER | 284 0.0005% | $19,439.80 | 0 | 43 | |
| Patel Kavita | director | 0 0% | $0 | 0 | 22 | |
| New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.176% | $461.71M | 2 | 0 | +40.21% |
| Novo Holdings A/S | 10 percent owner | 4016878 7.2509% | $274.96M | 1 | 0 | +6.58% |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 2.9943% | $113.54M | 1 | 1 | +6.58% |
| Carroll Jill | director | 1479148 2.67% | $101.25M | 1 | 6 | +6.58% |
| SANDELL SCOTT D | director | 0 0% | $0 | 0 | 2 | |
| BASKETT FOREST | director | 0 0% | $0 | 1 | 1 | +73.84% |
| Florence Anthony A. Jr. | director | 0 0% | $0 | 0 | 1 | |
| Makhzoumi Mohamad | director | 0 0% | $0 | 0 | 1 | |
| Ware Olivia C | director | 0 0% | $0 | 0 | 2 |
$66,736,176 | 136 | 27.54% | $3.71B | |
$11,583,737 | 45 | 49.75% | $3.16B | |
$224,382,625 | 44 | 27.62% | $3.53B | |
$140,165,669 | 33 | 85.24% | $4.02B | |
$1,275,975,557 | 32 | 19.44% | $4.49B | |
$5,066,938 | 27 | 26.38% | $3.45B | |
$150,253,463 | 26 | -52.83% | $3.97B | |
$137,027,226 | 13 | 28.32% | $3.82B | |
$177,517,505 | 13 | 16.65% | $4.5B | |
$9,976,473 | 12 | 29.52% | $4.02B | |
$1,248,715 | 10 | 5.66% | $3.75B | |
$1,711,150 | 9 | 31.59% | $4.36B | |
$32,575,266 | 8 | 37.03% | $3.47B | |
$4,623,072 | 7 | 11.07% | $3.52B | |
Arcellx, Inc. (ACLX) | $182,500,000 | 6 | 29.00% | $3.79B |
$461,215 | 5 | 10.35% | $4.06B | |
$24,000,085 | 4 | 33.26% | $3.54B | |
$7,600,000 | 1 | -4.05% | $3.35B | |
$49,999,992 | 1 | 50.02% | $4.14B |
| Increased Positions | 90 | +36.44% | 7M | +11.2% |
| Decreased Positions | 105 | -42.51% | 5M | -8.55% |
| New Positions | 29 | New | 651,635 | New |
| Sold Out Positions | 20 | Sold Out | 949,303 | Sold Out |
| Total Postitions | 232 | -6.07% | 63M | +2.65% |
| Gilead Sciences, Inc. | $488,670.00 | 11.59% | 6.72M | 0 | 0% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $461,880.00 | 10.95% | 6.35M | +4M | +226.81% | 2025-09-30 |
| Fmr Llc | $418,905.00 | 9.93% | 5.76M | -210,834 | -3.53% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $338,030.00 | 8.02% | 4.65M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $284,084.00 | 6.74% | 3.91M | -37,798 | -0.96% | 2025-09-30 |
| Blackrock, Inc. | $246,334.00 | 5.84% | 3.39M | -80,288 | -2.31% | 2025-09-30 |
| Nea Management Company, Llc | $221,421.00 | 5.25% | 3.05M | -700,000 | -18.69% | 2025-09-30 |
| Ra Capital Management, L.P. | $220,786.00 | 5.24% | 3.04M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $179,474.00 | 4.26% | 2.47M | -9,647 | -0.39% | 2025-09-30 |
| Sr One Capital Management, Lp | $170,623.00 | 4.05% | 2.35M | 0 | 0% | 2025-09-30 |